Five years after NeRRe Therapeutics spun out of GSK with some of its unwanted work in neurosciences, the UK biotech is executing a spinout of its own.
NeRRe has taken a neurokinin-1,3 receptor antagonist — with potential as a hormone replacement therapy — and hived it off into a new biotech called KaNDy Therapeutics. Now KaNDy will take it into a Phase IIb study for postmenopausal vasomotor symptoms.
Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed Advisors are backing the company.
KaNDy Chairman Iain Dukes had this to say:
The formation of KaNDy Therapeutics enables us to maximise the potential of NT-814 in a range of debilitating Women’s Health conditions. We believe NT-814 is one of the few true innovations in Women’s Health in more than two decades and potentially represents a major breakthrough in areas of significant unmet medical need such as PMVMS. Mary has built up an excellent team who have made substantial progress with NT-814 and we’re looking forward to advancing this exciting new product into a Phase 2b programme.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription